| Literature DB >> 26842862 |
Tamsyn Derrick1, Anna R Last2, Sarah E Burr3,4, Chrissy H Roberts5, Meno Nabicassa6, Eunice Cassama7, Robin L Bailey8, David C W Mabey9, Matthew J Burton10, Martin J Holland11.
Abstract
BACKGROUND: Trachoma, a preventable blinding eye disease, is initiated by ocular infection with Chlamydia trachomatis (Ct). We previously showed that microRNAs (miR) -147b and miR-1285 were up-regulated in inflammatory trachomatous scarring. During the initial stage of disease, follicular trachoma with current Ct infection, the differential expression of miR has not yet been investigated.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26842862 PMCID: PMC4739388 DOI: 10.1186/s12879-016-1367-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Yield of three ocular Ct strains in two epithelial cell lines. Chlamydial genome copy number of three ocular Ct strains (A2497, A2497p- and A/HAR-13) in HEp-2 and HCjE cells at 48 hpi. Cells were infected at an MOI of 1. Mock-infected cells (−VE) were treated identically except for the addition of Ct inoculum. The mean of the total OmcB genome copy number per well of 6 biological replicates is shown
Trachoma grade and Ct infection load of clinical samples
| FPC score | Total (% male) | Ct positive | Ct | Human RPP30 median copies/swab (IQR)b |
|---|---|---|---|---|
| Controls (N) | ||||
| F0P0C0 | 82 (41 %) | 5/82 (6 %) | 345 (42–1078) | 19290 (13310–25810) |
| TF cases: Breakdown by follicular score | ||||
| F2 | 46 (48 %) | 20/46 (43.5 %) | 703 (370–25870) | 23900 (15670–39440) |
| F3 | 35 (31 %) | 27/35 (77 %) | 6050 (1451–15350) | 35250 (19120–43250) |
| TF cases: Breakdown by papillary hypertrophy score | ||||
| P1 | 53 (38 %) | 22/53 (71 %) | 656 (433–5238) | 23280 (15380–34500) |
| P2 | 22 (55 %) | 19/22 (86 %) | 12950 (3638–42880) | 37750 (21560–48560) |
| P3 | 6 (17 %) | 6/6 (100 % | 11480 (4169–15720) | 43620 (37750–53440) |
aCt omcB median calculated from Ct positive individuals only
bIQR = inter-quartile range
Differential expression analysis of miR by qPCR in 163 clinical samples, in three independent phenotype comparisons
| TF ( | TF Ct + ( | TF Ct + ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| Adj Pa | FCb |
| Adj Pa | FCb |
| Adj Pa | FCb | |
| miR-184 | 5.69 x 10−8 | 7.96 x 10−7 | 0.30 | 0.7571 | 0.7571 | 0.88 | 3.06 x 10−7 | 1.07 x 10−6 | 0.28 |
| miR-142-5p | 6.46 x 10−7 | 4.52 x 10−6 | 1.82 | 1.63 x 10−5 | 7.58 x 10−5 | 2.53 | 2.3 x 10−12 | 3.22 x 10−11 | 2.83 |
| miR-155-5p | 1.56 x 10−5 | 7.29 x 10−5 | 1.73 | 9.45 x 10−6 | 6.62 x 10−5 | 2.50 | 1.18 x 10−9 | 5.51 x 10−9 | 2.58 |
| miR-150-5p | 0.0003 | 0.0011 | 1.56 | 1.41 x 10−6 | 1.98 x 10−5 | 3.24 | 8.56 x 10−10 | 5.51 x 10−9 | 2.71 |
| miR-181b-5p | 0.0010 | 0.0028 | 1.33 | 0.0018 | 0.005 | 1.74 | 1.58 x 10−6 | 4.44 x 10−6 | 1.70 |
| miR-342-3p | 0.0041 | 0.0096 | 1.12 | 0.0076 | 0.0178 | 1.50 | 0.0001 | 0.0002 | 1.34 |
| miR-4728-3p | 0.0103 | 0.0207 | 0.75 | 0.0353 | 0.0617 | 0.72 | 0.0005 | 0.0008 | 0.65 |
| miR-181a-5p | 0.0120 | 0.0211 | 1.30 | 0.0151 | 0.0301 | 1.40 | 0.0003 | 0.0006 | 1.54 |
| miR-375 | 0.0871 | 0.1355 | 0.80 | 0.3054 | 0.3887 | 0.81 | 0.0615 | 0.0862 | 0.75 |
| miR-132-3p | 0.1628 | 0.2279 | 1.09 | 0.0009 | 0.0031 | 1.45 | 0.0023 | 0.0035 | 1.27 |
| miR-10a-5p | 0.2654 | 0.3378 | 1.16 | 0.6729 | 0.7247 | 0.92 | 0.3454 | 0.4030 | 1.15 |
| miR-146b-3p | 0.5491 | 0.6406 | 0.95 | 0.3666 | 0.4277 | 1.15 | 0.9425 | 0.9425 | 1.02 |
| miR-147b | 0.6203 | 0.6680 | 1.07 | 0.1073 | 0.1669 | 1.44 | 0.2394 | 0.3047 | 1.21 |
| miR-1285 | 0.8683 | 0.8683 | 0.98 | 0.2095 | 0.2933 | 0.83 | 0.4434 | 0.4775 | 0.91 |
Tests for difference were conducted with a T test or Wilcoxon signed rank test if data were not normally distributed
N normal, TF follicular trachoma, Ct + Ct infected, Ct- no Ct infection detected
aP adj = Adjusted P value
bFC = Fold change
Fig. 2Patterns of differential miR expression according to clinical phenotype. MiR expression was measured using qPCR in 163 clinical samples. MiR labeled with double arrows had significant differences between groups (Padj < 0.05, FC > 1.5). MiR with single arrows had significantly different expression (Padj < 0.05) but had a FC <1.5 in 2 or 3 of the comparisons shown
Fig. 3MiR expression correlates with clinical inflammation score. Expression of miR-155 and miR-184 for 163 clinical samples plotted against clinical trachoma papillary hypertrophy score. P2 and P3 categories were combined due to the low number of P3 cases. ∆CT values were calculated by subtracting the endogenous control (snoRNA U6) cycle threshold (CT) value from the CT value of each miR for each individual sample. ∆CT values were inverted (40-∆CT) in order to show the direction of miR expression